Article citationsMore>>

M. Horger, L. Kanz, B. Denecke, et al., “The Benefit of Using Whole-Body, Low-Dose, Nonenhanced, Multidetector Computed Tomography for Follow-Up and Therapy Response Monitoring in Patients Whit Multiple Myeloma,”, Cancer, Vol. 109, No. 8, 2007, pp. 1617-1626. doi:10.1002/cncr.22572

has been cited by the following article:

• TITLE: Whole-Body 64-Slice Multidetector Computed Tomography (MDCT) Identifies High-Risk Myeloma

  AUTHORS: Giuseppe Mele, Grazia D’Agostino, Giacomo Loseto, Maria Rosaria Coppi, Angela Melpignano, Grazia Angone, Giovanni Quarta

  KEYWORDS: Asymptomatic Myeloma; MDCT; MRI; Conventional Radiography

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.3 No.7, December 31, 2012

  ABSTRACT: Background: In Multiple Myeloma (MM) the individuation of bone lesions at baseline is mandatory because the detection of cortical damage reflects prognostic implications. Conventional Radiography (CR) shows osteolytic bone lesions only when the cortical bone damage is more than 30%. Whole-body 64-slice multidetector computed tomography (MDCT) has recently been employed for detecting early osteolytic disease. Patients and Methods: Twenty-height patients with Asymptomatic MM according to IMWG criteria underwent a 64 MDCT. Results: In our experience MDCT revealed osteolysis in 14/28 patients with normal skeletal survey and in 6 patients with normal Magnetic Resonance Imaging (MRI). Patients with radiological evidence of bone disease on MDCT were at high risk of progression with a median time to progression of 5 months (range 1 - 26 months) in comparison with patients without radiological evidence of bone disease who, conversely, showed a median time to progression of 20 months (range 8 - 40 months) (P = 0.0001). Conclusions: MDCT is able to identify MM patients with a high risk of progression, who might benefit from early therapy.